R1 RCM Inc
NASDAQ:RCM

Watchlist Manager
R1 RCM Inc Logo
R1 RCM Inc
NASDAQ:RCM
Watchlist
Price: 14.31 USD 0.07% Market Closed
Market Cap: $6B

EV/EBITDA

15.6
Current
No historical data
Comparison unavailable

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.6
=
Enterprise Value
$8B
/
EBITDA
$514.1m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.6
=
Enterprise Value
$8B
/
EBITDA
$514.1m

Valuation Scenarios

R1 RCM Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (15.6), the stock would be worth $14.31 (0% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-17%
Maximum Upside
+5%
Average Downside
5%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 15.6 $14.31
0%
3-Year Average 15.6 $14.31
0%
5-Year Average 16.4 $15.06
+5%
Industry Average 12.9 $11.83
-17%
Country Average 14.4 $13.18
-8%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$8B
/
Oct 2024
$514.1m
=
15.6
Current
$8B
/
Dec 2024
$574.7m
=
13.9
Forward
$8B
/
Dec 2025
$746.3m
=
10.7
Forward
$8B
/
Dec 2026
$818m
=
9.8
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
R1 RCM Inc
NASDAQ:RCM
6B USD 15.6 -98.7
US
CVS Health Corp
NYSE:CVS
98.3B USD 14.1 55.6
US
Cigna Group
XMUN:CGN
69.3B EUR 7.8 13.4
US
Cigna Corp
NYSE:CI
72.9B USD 0 12.2
DE
Fresenius SE & Co KGaA
XETRA:FRE
24.4B EUR 9.7 19.3
DE
Fresenius Medical Care AG
XMUN:FME
23.2B EUR 9.1 23.8
US
Laboratory Corporation of America Holdings
NYSE:LH
22.5B USD 12.3 25.6
US
Quest Diagnostics Inc
NYSE:DGX
22.6B USD 12.3 22.8
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.1B EUR 5.4 11.3
US
Guardant Health Inc
NASDAQ:GH
11.8B USD -31 -28.4
US
DaVita Inc
NYSE:DVA
10.3B USD 7.1 13.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
R1 RCM Inc
NASDAQ:RCM
Average EV/EBITDA: 10.4
15.6
15%
1
US
CVS Health Corp
NYSE:CVS
14.1
28%
0.5
US
C
Cigna Group
XMUN:CGN
7.8
5%
1.6
US
Cigna Corp
NYSE:CI
Not Available N/A N/A
DE
Fresenius SE & Co KGaA
XETRA:FRE
9.7
10%
1
DE
Fresenius Medical Care AG
XMUN:FME
9.1
7%
1.3
US
Laboratory Corporation of America Holdings
NYSE:LH
12.3
10%
1.2
US
Quest Diagnostics Inc
NYSE:DGX
12.3
6%
2
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
5.4
7%
0.8
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -31 N/A N/A
US
DaVita Inc
NYSE:DVA
7.1
4%
1.8
P/E Multiple
Earnings Growth PEG
US
R1 RCM Inc
NASDAQ:RCM
Average P/E: 22
Negative Multiple: -98.7
253%
N/A
US
CVS Health Corp
NYSE:CVS
55.6
90%
0.6
US
C
Cigna Group
XMUN:CGN
13.4
19%
0.7
US
Cigna Corp
NYSE:CI
12.2
19%
0.6
DE
Fresenius SE & Co KGaA
XETRA:FRE
19.3
25%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
23.8
15%
1.6
US
Laboratory Corporation of America Holdings
NYSE:LH
25.6
27%
0.9
US
Quest Diagnostics Inc
NYSE:DGX
22.8
12%
1.9
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.3
15%
0.8
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -28.4 N/A N/A
US
DaVita Inc
NYSE:DVA
13.8
19%
0.7

Market Distribution

In line with most companies in the United States of America
Percentile
54th
Based on 9 875 companies
54th percentile
15.6
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

R1 RCM Inc
Glance View

R1 RCM Inc. emerged as a formidable entity in the labyrinthine world of healthcare revenue cycle management, catering to the sprawling intricacies of financial and administrative healthcare operations. The company strategically positions itself as a vital bridge between healthcare providers and the convoluted landscape of billing, insurance claims, and patient payments. By deploying advanced technology platforms and analytics, R1 RCM enhances the efficiency of revenue cycles and streamlines operations for hospitals and physician groups. Its tailored solutions aim to minimize errors, expedite claim submissions, and ultimately maximize revenue collection in an industry often plagued by inefficiencies and regulatory burdens. At the core of R1 RCM's operations is its model of managing the complete revenue cycle on behalf of healthcare clients, transforming a traditionally fragmented process into a cohesive system. The company monetizes this service through long-term partnerships where it shares in the financial gains achieved, ensuring that its interests align with those of its clients. By taking over everything from patient registration and insurance verification to billing and collections, R1 RCM liberates healthcare providers to focus on patient care rather than financial logistics. This comprehensive approach not only fortifies the financial health of its clients but also embeds R1 RCM deeply into the operational fabric of modern healthcare institutions.

RCM Intrinsic Value
10.87 USD
Overvaluation 24%
Intrinsic Value
Price $14.31
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett